Overview

• Hospital Álvaro Cunqueiro treated a man in his 40s with severe Hemophilia B on June 18, marking the first public-hospital use of Hemgenix in Spain
• Etranacogen dezaparvovec delivers a functional copy of the factor IX gene to liver cells via a modified viral vector, enabling continuous production of the clotting protein
• Xunta de Galicia invested 15.6 million euros to secure the therapy, with payments spread over five years and contingent on clinical outcomes
• Access is restricted to adult patients without factor IX inhibitors who have undergone at least two years of extended half-life prophylaxis
• Sergas anticipates that up to eight patients in Galicia will meet the stringent criteria to receive this functional cure therapy